Amgen (AMGN) Change in Intangibles (2014 - 2015)

Amgen (AMGN) posted quarterly Change in Intangibles of $5.0 million for Q3 2015, down 96.3% on a QoQ basis from $135.0 million in Q4 2014.

Amgen (AMGN) Change in Intangibles (2014 - 2015) Analysis & Trends

Amgen (AMGN) has reported Change in Intangibles for 2 consecutive years, with $5.0 million the latest figure, recorded in Q3 2015.

In Q3 2015, Change in Intangibles changed N/A year-over-year to $5.0 million; the TTM figure through Dec 2015 stood at $140.0 million (changed N/A YoY), while the FY2016 annual figure was $99.0 million, up 80.0% from the prior year.
Change in Intangibles came in at $5.0 million for Q3 2015 at Amgen, down from $135.0 million in the prior quarter.
The five-year high for Change in Intangibles was $135.0 million in Q4 2014, with the low at $5.0 million in Q3 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Intangibles (Qtr)
1	Eli Lilly	1,066.16 Bn	1,060.88 Bn	16.22 Bn	-
2	Johnson & Johnson	611.69 Bn	589.64 Bn	15.96 Bn	-
3	AbbVie	444.34 Bn	434.99 Bn	10.78 Bn	-
4	Astrazeneca	284.94 Bn	277.05 Bn	12.61 Bn	-991.00 Mn
5	Merck	224.23 Bn	218.58 Bn	12.09 Bn	-
6	Amgen	195.12 Bn	183.08 Bn	5.87 Bn	-
7	Gilead Sciences	156.45 Bn	148.73 Bn	5.52 Bn	-
8	Pfizer	136.01 Bn	123.24 Bn	-1.21 Bn	-
9	Novartis Ag	113.45 Bn	113.67 Bn	-	-461.00 Mn
10	Biogen	30.87 Bn	26.59 Bn	1.82 Bn	-

Download Data